NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.5820
-0.0028 (-0.48%)
At close: 3:59PM EST

0.5800 -0.00 (-0.34%)
After hours: 5:57PM EST

Stock chart is not supported by your current browser
Previous Close0.5848
Open0.5820
Bid0.5800 x 2200
Ask0.0000 x 900
Day's Range0.5610 - 0.6000
52 Week Range0.2300 - 4.0400
Volume289,281
Avg. Volume944,414
Market Cap16M
Beta (3Y Monthly)4.96
PE Ratio (TTM)N/A
EPS (TTM)-0.4570
Earnings DateNov 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.30
  • Business Wire

    NovaBay Pharmaceuticals Launches NovaWipes Eyelid Wipes on Amazon.com

    Avenova Direct, NovaBay’s prescription-strength lid and lash spray, is also available on Amazon.com without a prescription. “Our soft and absorbent NovaWipes are perfect for applying Avenova to eyelids irritated by the symptoms of dry eye and blepharitis,” said Justin Hall, NovaBay CEO. “NovaWipes represent the second of several Avenova Direct line extensions and complementary products we are introducing to drive cost-effective growth and leverage our distribution infrastructure,” said Hall.

  • Business Wire

    NovaBay Pharmaceuticals Launches NovaSight™ Daily Vitamin for Ocular Health on Amazon.com

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the launch of NovaSight™, a proprietary daily vitamin and mineral supplement specially formulated to support ocular health, on Amazon.com. NovaSight is a companion product to Avenova® Direct, NovaBay’s prescription-strength lid and lash spray available on Amazon.com without a prescription. NovaSight was formulated by well-known, board-certified ophthalmologist Robert Abel, Jr., M.D., to replenish vital eye nutrients.

  • Business Wire

    NovaBay Pharmaceuticals Reports 2019 Third Quarter Financial Results

    Conference call begins at 4:30 p.m. Eastern time today

  • Business Wire

    NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures

    CelleRx is a skin and wound cleanser based on NovaBay’s proprietary pure hypochlorous formulation, and is proven to gently clean and ease discomfort following aesthetic dermatology and cosmetic surgery procedures. “We are delighted to make prescription-strength CelleRx available without a prescription directly to customers through our new website,” said Justin Hall, NovaBay CEO. “CelleRx has all the characteristics of a successful skin and wound cleanser: it is known to quickly kill bacteria in vitro, it prevents the build-up of biofilm that can delay wound healing and it is safe for underlying tissue.

  • Business Wire

    NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial results after market close on Thursday, November 7, 2019 and will hold an investment community conference call that day.

  • NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies
    Business Wire

    NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies

    The NuLids System is a hand-held, cordless device that safely and effectively removes accumulated scurf from eyelashes and eyelids, while stimulating meibomian gland production in dry eye and blepharitis patients. The NuLids System is available through eyecare professionals for home use by the patient.

  • Market Exclusive

    Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests

    British High Court Rules Against Johnson Parliament Prorogation Apparently, proroguing Parliament was not Boris Johnson’s prerogative. The British high court ruled today that the Prime Minister acted unlawfully in suspending Parliament until October 14th, and that he misled the Queen in advising that Parliament should be suspended. Johnson is now facing calls to resign, which […]The post Market Morning: Prorogation Ruled Rogue, High Demand for Fed Repo, New Breast Cancer Tests appeared first on Market Exclusive.

  • GlobeNewswire

    NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock

    The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock convertible from the preferred stock, the accompanying warrants and the common stock issuable upon exercise of the warrants  will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

  • GlobeNewswire

    NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 4,198,566 shares of common stock at a price of $1.00 per share in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to one share of common stock for each share purchased with an exercise price of $1.15 per share. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American: LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

  • Benzinga

    NovaBay Trades Higher After Compliance Plan Accepted By NYSE

    NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange. NYSE notified NovaBay on April 12 and May 16 that it was out of compliance with exchange listing requirements. NYSE has determined NovaBay has made a reasonable demonstration of its ability to make progress toward regaining compliance by October 12, 2020.

  • Business Wire

    NovaBay Pharmaceuticals Raises $2.4 Million in a Private Placement

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces the closing of a private placement of common stock and warrants with accredited investors, raising gross proceeds of $2.4 million. NovaBay also announces an extension of the maturity date of a $1 million loan agreement with Pioneer Pharma (Hong Kong) Company Limited from July 27, 2019 to July 1, 2020. Investors in the private placement purchased 1,371,427 units at a price of $1.75 per unit.

  • Business Wire

    NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh as Chief Financial Officer. Hall has served as interim President and CEO, and Raleigh as interim CFO since March 2019.

  • Business Wire

    NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that Avenova® Direct is available at affordable pricing and without a prescription on Amazon.com through the Company’s new direct-to-consumer online channel. Avenova, the leading lid and lash spray, is designed for the removal of bacteria and debris on and around the eyelid margin that contribute to bacterial eye infections, which represent approximately 85% of the dry eye market.

  • Business Wire

    NovaBay Pharmaceuticals Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that on May 16, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide requiring stockholders’ equity of $2.0 million or more and $4.0 million or more, respectively, if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years. According to the Exchange, this notice does not impact the Company’s ongoing plan to regain compliance with continued listing standards, which requires the Company to regain such compliance by October 12, 2020 or be subject to delisting procedures.

  • Business Wire

    NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire

    NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019

    Management to discuss new partner pharmacy program and expanded access to in-office direct channel

  • Business Wire

    NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m. Pacific time. Registered holders and beneficial stockholders, who register for the meeting in advance, will be able to participate in the meeting, vote and submit questions during the meeting via a live webcast by visiting www.meetingcenter.io/263757134. The Company also notes that on April 12, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.